

找到约 3,460 条结果 (用时 0.87 秒)

## Google 学术 : Benefit of everolimus in the treatment of intrahepatic cholangiocarcinoma patient with PIK3CA mutation: A case report

Targeting the phosphoinositide-3 (PI3) kinase pathway ... - Baselga - 被引用次数 : 165

... targeted therapy of intrahepatic cholangiocarcinomas ... - Ross - 被引用次数 : 80

Toward personalized treatment of advanced biliary ... - Geynisman - 被引用次数 : 28

## Toward Personalized Treatment of Advanced Biliary Tract Cancers ...

[www.discoverymedicine.com/.../toward-personalized-treatment-of-advanced...](http://www.discoverymedicine.com/.../toward-personalized-treatment-of-advanced...) [▼ 翻译此页](#)

作者 : DM Geynisman - 2012 - 被引用次数 : 28 - 相关文章

2012年7月26日 - A 1996 trial of 90 patients with advanced pancreatic and biliary cancers of .... A case report demonstrated the feasibility of combining gemcitabine with .... In BTC, 1 PIK3CA mutation in 11 IHCC and 1 in 23 GBCs was reported (Riener et al., 2008). .... and progression of intrahepatic cholangiocarcinoma.

## New Routes to Targeted Therapy of Intrahepatic ... - NCBI

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461/> - [翻译此页](#)

作者 : JS Ross - 2014 - 被引用次数 : 81 - 相关文章

2014年2月21日 - Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that is rarely ... Two thirds of patients in this study harbored genomic alterations that are ... an effective therapy that would be broadly applicable to the treatment of ICC. .... In this study, 12% of the cases featured a mutation or splicing ...

## Targeted Therapy in Biliary Tract Cancers

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者 : A Merla - 2015 - 被引用次数 : 8 - 相关文章

2015年8月13日 - A subsequent meta-analysis concluded that BTC patients treated with ...

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 33711

**Manuscript Type:** Case Report

**Benefit of everolimus in the treatment of intrahepatic cholangiocarcinoma patient with PIK3CA mutation: A case report**

Ji-Lai Bian, Mei-Mei Wang, En-Juan Tong, Jing Sun, Ming Li, Zhi-Bo Miao, Yan-Lin Li, Bai-Hong Zhu, Jia-Jia Xu

### Abstract

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare liver cancer with poor prognosis. The therapeutic options for patients with advanced ICC are limited and usually ineffective. There is currently no approved targeted

### Match Overview

1	<b>Internet</b> 80 words crawled on 03-May-2017 <a href="http://www.cancer.gov">www.cancer.gov</a>	3%
2	<b>Internet</b> 54 words crawled on 23-Apr-2009 <a href="http://www.pubmedcentral.nih.gov">www.pubmedcentral.nih.gov</a>	2%
3	<b>Internet</b> 42 words crawled on 29-Apr-2014 <a href="http://www.rare-cancer.org">www.rare-cancer.org</a>	2%
4	<b>Crossref</b> 40 words Young, Regina M, and M Celeste Simon. "Untuning the ... umor metabolic machine: HIF- $\alpha$ : pro- and antitumorigeni	2%
5	<b>Internet</b> 34 words crawled on 23-Oct-2015 <a href="http://www.voicesagainstbraincancer.org">www.voicesagainstbraincancer.org</a>	1%
6	<b>Crossref</b> 34 words Maithel, Shishir K., T. Clark Gamblin, Ihab Kamel, Celia Pamela Corona-Villalobos, Melanie Thomas, and Timot	1%
7	<b>Crossref</b> 20 words Yazbeck, V.Y. "Temsirrolimus downregulates p21 without altering cyclin D1 expression and induces autophagy & ...	1%
8	<b>Internet</b> 18 words crawled on 11-Apr-2016 <a href="http://www.impactjournals.com">www.impactjournals.com</a>	1%

Benefit of everolimus in the treatment of intrahepatic cholangiocarcinoma patient



全部 图片 视频 新闻 地图 图书

找到约 4,620 条结果

时间不限

- 过去 1 小时内
- 过去 24 小时内
- 过去 1 周内
- 过去 1 个月内
- 过去 1 年内

所有结果

精确匹配

[Prospective phase II trial of everolimus in PIK3CA amplification ...](https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3196-6)

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3196-6>

23 Mar 2017 ... PIK3CA amplification/mutation PTEN loss everolimus ... who would receive the most benefit from everolimus treatment. ... The additional case inclusion criteria were as follows: (1) age over 18; ... cancer (CRC), pancreatic cancer and cholangiocarcinoma. ... Baseline Characteristics of patients in this study ...

[Biliary cancer: intrahepatic cholangiocarcinoma vs ... - NCBI - NIH](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401855/)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401855/>

1 Oct 2016 ... While pre-clinical studies and isolated case reports have ... Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. ... Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer ... Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

[Toward Personalized Treatment of Advanced Biliary Tract Cancers ...](http://www.discoverymedicine.com/2012/07/26/toward-personalized-treatment-of-advanced-biliary-tract-cancers/)

[www.discoverymedicine.com/2012/07/26/toward-personalized-treatment-of-advanced-biliary-tract-cancers/](http://www.discoverymedicine.com/2012/07/26/toward-personalized-treatment-of-advanced-biliary-tract-cancers/)

26 Jul 2012 ... A case report demonstrated the feasibility of combining gemcitabine with cetuximab ... Further studies are required to assess whether there may be benefit in certain subsets of patients. ... In BTC, 1 PIK3CA mutation in 11 IHCC and 1 in 23 GBCs was ... and progression of intrahepatic cholangiocarcinoma.

[HTML - Journal of Gastrointestinal Oncology - AME Publishing ...](http://jgo.amegroups.com/article/view/10269/html)

[jgo.amegroups.com/article/view/10269/html](http://jgo.amegroups.com/article/view/10269/html)

Keywords: Next generation sequencing; targetable mutations; biliary cancers ( BCs) ... survival benefit in comparison to gemcitabine monotherapy with similar rates of ... Despite this, the vast majority of patients develop treatment resistance after few ... While pre-clinical studies and isolated case reports have demonstrated ...

[All](#)[Images](#)[News](#)[Videos](#)[Shopping](#)[More](#)[Settings](#)[Tools](#)

About 4,620 results (0.77 seconds)

### Prospective phase II trial of everolimus in PIK3CA amplification ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363054/>

by ST Kim - 2017

23 Mar 2017 - Most of the **patients** (50.0%) had gastric cancer (GC) as the site of their primary tumor followed by colorectal cancer (CRC), pancreatic cancer, and **cholangiocarcinoma**. ... Keywords: **PIK3CA** amplification/**mutation**, PTEN loss, **everolimus** ... who would receive the most **benefit** from **everolimus treatment**.

Missing: **intrahepatic**

### Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic ...

[journals.plos.org/plosone/article?id=10.1371/journal.pone.0115383](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115383) ▼

by CR Churi - 2014 - Cited by 68 - Related articles

23 Dec 2014 - **Patients** with targetable **mutations** were referred to appropriate clinical trials. ... In **intrahepatic** CCA, KRAS, TP53 or MAPK/mTOR GAs were significantly ... Radiologic responses and clinical **benefit** was noted with EGFR, FGFR, C-met, ... In addition, all **cases** with BAP1 **mutation** were **treated** with systemic ...

Missing: **everolimus**

### Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic ...

[jgo.amegroups.com/article/view/10269/html](http://jgo.amegroups.com/article/view/10269/html) ▼

by DH Ahn - 2016

Keywords: Next generation sequencing; targetable **mutations**; biliary cancers (BCs) ... survival **benefit** in comparison to gemcitabine monotherapy with similar rates of ... Despite this, the vast majority of **patients** develop **treatment** resistance after few ... While pre-clinical studies and isolated **case reports** have demonstrated ...

### Toward Personalized Treatment of Advanced Biliary Tract Cancers ...

[www.discoverymedicine.com/.../toward-personalized-treatment-of-advanced-biliary-t...](http://www.discoverymedicine.com/.../toward-personalized-treatment-of-advanced-biliary-t...) ▼

by DM Geynisman - 2012 - Cited by 33 - Related articles

26 Jul 2012 - A **case report** demonstrated the feasibility of combining gemcitabine with cetuximab ...

Further studies are required to assess whether there may be **benefit** in certain subsets of **patients**